Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 29;7(5):698-708.
doi: 10.1002/ags3.12711. eCollection 2023 Sep.

Essential updates 2021/2022: Perioperative and surgical treatments for gastric and esophagogastric junction cancer

Yoshitomo Yanagimoto  1 , Yukinori Kurokawa  2 , Yuichiro Doki  2
Affiliations
Review

Essential updates 2021/2022: Perioperative and surgical treatments for gastric and esophagogastric junction cancer

Yoshitomo Yanagimoto et al. Ann Gastroenterol Surg. .

Abstract

In recent years, important clinical trials for gastric cancer (GC) and esophagogastric junction cancer (EGJC) have been reported, changing the strategies of surgical and perioperative treatment. Although laparoscopic gastrectomy has already been shown to be effective for early-stage cancer, recent evidence from both Asia (JLSSG0901, CLASS-01 and KLASS-02) and Europe (LOGICA and STOMACH trials) has demonstrated that it is useful for advanced GC. Robotic surgery has been rapidly gaining popularity in recent years, and randomized controlled trials are ongoing to evaluate its efficacy. A prospective nationwide multicenter study mapped sites with frequent metastasis and revealed lymphatic flow specific to EGJC, thus establishing the optimal lymph node dissection area and surgical approach based on esophageal involvement. Perioperative chemotherapy, the mainstay of treatment in Europe, also has been established in Asia by the PRODIGY and RESOLVE studies. New clinical trials have been conducted to evaluate the efficacy of combining immunotherapy or molecular-targeted therapy with perioperative chemotherapy or chemoradiotherapy. In this review, we present important recent clinical trials regarding the treatment of GC and EGJC published in 2021 or 2022.

Keywords: adjuvant treatment; esophagogastric junction cancer; gastric cancer; minimally invasive surgery; neoadjuvant treatment; perioperative treatment; robotic surgery.

PubMed Disclaimer

Conflict of interest statement

Y. Yanagimoto has declared no conflicts of interest. Y. Kurokawa is an Associate Editor of the Annals of Gastroenterological Surgery. Y. Doki is an Editorial Board member of the Annals of Gastroenterological Surgery.

References

    1. Hashimoto T, Kurokawa Y, Mori M, Doki Y. Update on the treatment of gastric cancer. JMA J. 2018;1(1):40–9. - PMC - PubMed
    1. Song Y, Liu X, Cheng W, Li H, Zhang D. The global, regional and national burden of stomach cancer and its attributable risk factors from 1990 to 2019. Sci Rep. 2022;12(1):11542. - PMC - PubMed
    1. Yamashita H, Seto Y, Sano T, Makuuchi H, Ando N, Sasako M, et al. Results of a nation‐wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma. Gastric Cancer. 2017;20(Suppl 1):69–83. - PubMed
    1. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al. D2 lymphadenectomy alone or with Para‐aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359(5):453–62. - PubMed
    1. Sano T, Sasako M, Mizusawa J, Yamamoto S, Katai H, Yoshikawa T, et al. Randomized controlled trial to evaluate splenectomy in Total gastrectomy for proximal gastric carcinoma. Ann Surg. 2017;265(2):277–83. - PubMed

LinkOut - more resources